Singapore MedTech Startup Launches Strategic Research Collaboration with Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System

Strategic Research Collaboration initiated with Clinicians from Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System

[Singapore]-
NDR Medical Technology, an interventional robotics company, is proud to
announce a strategic research collaboration with interventional radiologists Dr.
Sirish A. Kishore, Dr. Rajesh Shah, and the Veterans Affairs Palo Alto Health
Care System (VAPAHCS). This collaboration will benefit the large volume of
complex cancer patients at VAPAHCS and aims to validate the performance of
NDR’s latest innovative automated needle targeting (ANT) technology,
specifically the NDAnalyzer and NDPathfinder AI software for percutaneous
oncologic procedures

NDAnalyzer
generates a 3D model of a patient’s anatomy using CT scans and detects nodules
for biopsy or ablation, while NDPathfinder proposes a safe needle trajectory
path to target nodules while bypassing vital organs and tissues. The research
collaboration will evaluate and validate the performance of NDR’s ANT-C
AI-based medical software for planning transthoracic needle placements in lung
biopsies.

“Through
this collaboration, we aim to push the boundaries of medical technology and
bring cutting-edge solutions to patients,” said Alan Goh, CEO and
Co-Founder of NDR Medical. ” This partnership goes beyond validating the
capabilities of the software in detecting cancer nodules and the planning of an
optimal trajectory access path. It represents our commitment to advance this
technology in the US market, as we strive to improve patient outcomes and
transform the world’s healthcare industry.”

Dr.
Kishore, Clinical Assistant Professor of Radiology at the Stanford University
School of Medicine, will be the Principal Investigator for this study. He highlights,
“As medical technology continues to support more advanced and complex
image-guided procedures, AI has great potential to advance interventional
radiology and image-guided surgery. For
percutaneous oncology procedures such as biopsy and ablation, for example, we
are eager to explore the potential benefits in efficiency and accuracy of target
identification and path planning. I am excited to be a part of this
collaborative effort with NDR Medical to develop the most advanced technologies
in medical AI and robotics.”

Upon
completion of this retrospective study, the parties intend to develop further
collaboration in terms of prospective studies, culminating in AI-empowered
robotic assisted needle placements for targeted biopsies and other procedural
indications such as therapeutic tumor ablation.

About NDR Medical Technology

NDR Medical Technology was founded in 2015 and developed the patented Automated Needle Targeting system (ANT) that can facilitate safe and accurate needle punctures to organs such as the lungs, kidney, pancreas, and spine. Integrating AI and robotics, we empower surgeons to conduct pioneer image-guided robotic procedures with improved accuracy, precision, and safety for patients.

Our first interventional robot (ANT-X) integrates C-arm fluoroscopy and AI software to assist clinicians in percutaneous needle placements and can be used in a wide range of procedures such as urology, neurology, and orthopedics. ANT-C is a smart lesion targeting system that AI uses CT-can images to automate lesion detection, needle path planning and needle targeting with unparalleled precision and accuracy. Applications include usages in pulmonology and hepatology. As a cut above the rest, our robots cost less than half of the current technology out in the market and can function without the need for external sensors.

With a renewed vision to lead AI-empowered interventional robotics, we strive to create revolutionary breakthroughs in the industry and transform the healthcare landscape.

Evangeline Chia
evangeline@ndrmedical.com

This press release has also been published on VRITIMES